EFFECT OF SIMVASTATIN ON THE APPARENT SIZE OF LDL PARTICLES IN PATIENTS WITH TYPE-IIB HYPERLIPOPROTEINEMIA

被引:28
作者
ZHAO, SP
HOLLAAR, L
VANTHOOFT, FM
SMELT, AHM
LEUVEN, JAG
VANDERLAARSE, A
机构
[1] LEIDEN UNIV HOSP,DEPT CARDIOL,RIJNSBURGERWEG,BLDG 1,C5 P24,2333 AA LEIDEN,NETHERLANDS
[2] LEIDEN UNIV HOSP,DEPT INTERNAL MED,2333 AA LEIDEN,NETHERLANDS
[3] TNO,GAUBIUS INST,LEIDEN,NETHERLANDS
关键词
LOW DENSITY LIPOPROTEIN; LDL PARTICLE SIZE; TYPE-IIB HYPERLIPOPROTEINEMIA; SIMVASTATIN;
D O I
10.1016/0009-8981(91)90283-I
中图分类号
R446 [实验室诊断]; R-33 [实验医学、医学实验];
学科分类号
1001 ;
摘要
After 15 weeks of simvastatin therapy (20 mg/day), low density lipoprotein particle size in sera of 16 patients with type IIb hyperlipoproteinemia increased significantly from 233 +/- 5.0 angstrom to 237 +/- 7.0 angstrom (P < 0.05), analyzed by 2-16% polyacrylamide gradient gel electrophoresis. Under simvastatin therapy the concentrations of total cholesterol, total triglyceride, very low density lipoprotein cholesterol and triglyceride, low density lipoprotein cholesterol and apolipoprotein B in serum fell significantly by 30%, 30%, 43%, 28%, 36% and 26%, respectively, and the concentration of high density lipoprotein cholesterol rose significantly by 14%. The changes of low density lipoprotein particle size induced by simvastatin therapy were correlated best with the changes of very low density lipoprotein triglyceride concentration (r2 = 0.438, P < 0.01). Our results suggest that simvastatin therapy, additionally to a reduction of the serum cholesterol concentration, increases low density lipoprotein particle size which may contribute to reduction of the risk of coronary heart disease in patients with type IIb hyperlipoproteinemia.
引用
收藏
页码:109 / 118
页数:10
相关论文
共 27 条
[1]   EQUILIBRIUM BANDING OF LOW-DENSITY LIPOPROTEINS .3. STUDIES ON NORMAL INDIVIDUALS AND EFFECTS OF DIET AND HEPARIN-INDUCED LIPASE [J].
ADAMS, GH ;
SCHUMAKER, VN .
BIOCHIMICA ET BIOPHYSICA ACTA, 1970, 210 (03) :462-+
[2]  
AUSTIN M A, 1989, American Journal of Human Genetics, V45, pA234
[3]  
AUSTIN MA, 1988, AM J HUM GENET, V43, P838
[4]  
AUSTIN MA, 1988, JAMA-J AM MED ASSOC, V260, P1917
[5]   TREATMENT OF HYPERCHOLESTEROLEMIA WITH THE HMG COA REDUCTASE INHIBITOR, SIMVASTATIN [J].
BERGER, GMB ;
MARAIS, AD ;
SEFTEL, HC ;
BAKER, SG ;
MENDELSOHN, D ;
WELSH, NH ;
JOFFE, BI .
CARDIOVASCULAR DRUGS AND THERAPY, 1989, 3 (02) :219-227
[6]  
CHAPMAN MJ, 1988, J LIPID RES, V29, P442
[7]  
CROUSE JR, 1985, J LIPID RES, V26, P566
[8]   ABNORMALITIES IN VERY LOW, LOW, AND HIGH-DENSITY LIPOPROTEINS IN HYPERTRIGLYCERIDEMIA - REVERSAL TOWARD NORMAL WITH BEZAFIBRATE TREATMENT [J].
EISENBERG, S ;
GAVISH, D ;
OSCHRY, Y ;
FAINARU, M ;
DECKELBAUM, RJ .
JOURNAL OF CLINICAL INVESTIGATION, 1984, 74 (02) :470-482
[9]   HETEROGENEITY OF PLASMA LOW-DENSITY LIPOPROTEINS MANIFESTATIONS OF THE PHYSIOLOGIC PHENOMENON IN MAN [J].
FISHER, WR .
METABOLISM-CLINICAL AND EXPERIMENTAL, 1983, 32 (03) :283-291
[10]   GENETIC DETERMINANT OF PHENOTYPIC VARIANCE OF MOLECULAR-WEIGHT OF LOW-DENSITY LIPOPROTEIN [J].
FISHER, WR ;
HAMMOND, MG ;
MENGEL, MC ;
WARMKE, GL .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1975, 72 (06) :2347-2351